Infection risk in inflammatory bowel disease patients treated with vedolizumab: a systematic review and meta-analysis - Takeaways - MDSpire

Infection risk in inflammatory bowel disease patients treated with vedolizumab: a systematic review and meta-analysis

  • By

  • Lidan Zhang

  • Xiaogang Hao

  • Yidan Cui

  • Wenjian Yan

  • Kun Shang

  • Xin Zhang

  • June 11, 2026

  • 0 min

Share

  • 1

    The systematic review included 66 studies with 24,000 patients to assess infection risk associated with vedolizumab in inflammatory bowel disease.

  • 2

    The overall pooled infection incidence for vedolizumab was 13.08%, with respiratory tract infections being the most common at 4.25%.

  • 3

    Vedolizumab showed no significant difference in infection risk compared to TNF inhibitors or placebo, but had a higher risk compared to ustekinumab.

  • 4

    Serious systemic and rare infections were infrequent among patients treated with vedolizumab.

  • 5

    Meta-regression identified study design and geographic region as significant moderators of infection risk in vedolizumab-treated patients.

Original Source(s)

Infection risk in inflammatory bowel disease patients treated with vedolizumab: a systematic review and meta-analysis

  • by Lidan Zhang, Xiaogang Hao, Yidan Cui, Wenjian Yan, Kun Shang, Xin Zhang

  • June 11, 2026

Related Content

Integrating Double-Balloon Enteroscopy into the Diagnostic Pathway for Suspected Small Bowel Crohn’s Disease: A Retrospective Study from a Tertiary Care Center

Side Effects: Four Studies Worth Passing On

Kissing celiacs, Ozempic genes, Viagra for the brain, and a UTI test that actually works. This week's evidence is weird, useful, and worth your time.

Commentary: SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo